Table 1.
Composition of the prostate prognosis tissue microarray. Percentage in the column “Study cohort on TMA” refers to the fraction of samples across each category. Percentage in column “Biochemical relapse among categories” refers to the fraction of samples with biochemical relapse within each parameter in the different categories
| No. of patients (%) | ||
|---|---|---|
| Study cohort on TMA (n = 17,747) |
Biochemical relapse among categories | |
| Follow-up (mo) | ||
| n | 14,464 (81.5%) | 3612 (25%) |
| Mean | 56.3 | – |
| Median | 48 | – |
| Age (y) | ||
| ≤ 50 | 433 (2.4%) | 66 (15.2%) |
| 51–59 | 4341 (24.5%) | 839 (19.3%) |
| 60–69 | 9977 (56.4%) | 2073 (20.8%) |
| ≥ 70 | 2936 (16.6%) | 634 (21.6%) |
| Pretreatment PSA (ng/ml) | ||
| < 4 | 2225 (12.6%) | 313 (14.1%) |
| 4–10 | 10,520 (59.6%) | 1696 (16.1%) |
| 10–20 | 3662 (20.8%) | 1043 (28.5%) |
| > 20 | 1231 (7%) | 545 (44.3%) |
| pT stage (AJCC 2002) | ||
| pT2 | 11,518 (65.2%) | 1212 (10.5%) |
| pT3a | 3842 (21.7%) | 1121 (29.2%) |
| pT3b | 2233 (12.6%) | 1213 (54.3%) |
| pT4 | 85 (0.5%) | 63 (74.1%) |
| Gleason grade | ||
| ≤ 3 + 3 | 3570 (20.3%) | 264 (7.4%) |
| 3 + 4 | 9336 (53%) | 1436 (15.4%) |
| 3 + 4 Tert.5 | 798 (4.5%) | 165 (20.7%) |
| 4 + 3 | 1733 (9.8%) | 683 (39.4%) |
| 4 + 3 Tert.5 | 1187 (6.7%) | 487 (41%) |
| ≥ 4 + 4 | 999 (5.7%) | 531 (53.2%) |
| pN stage | ||
| pN0 | 10,636 (89.4%) | 2243 (21.1%) |
| pN+ | 1255 (10.6%) | 700 (55.8%) |
| Surgical margin | ||
| Negative | 14,297 (80.8%) | 2307 (16.1%) |
| Positive | 3388 (19.2%) | 1304 (38.5%) |
Numbers do not always add up to 17,747 in the different categories because of cases with missing data. Abbreviation: AJCC American Joint Committee on Cancer